Alopecia, Breast Cancer
Conditions
Keywords
persistent alopecia, docetaxel, breast cancer
Brief summary
Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described. This pilot trial explores the capacity of a cooling cap (Elasto-gel) to prevent persistent alopecia in breast cancer patients treated with adjuvant docetaxel regimens.
Detailed description
Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described. Docetaxel is toxic to skin and skin annexes and can produce nail toxicity and persistent alopecia. Nail toxicity has been successfully prevented by means of hypothermic gloves and slippers (Elasto-gel, Southwest Technologies, Inc, North Kansas City, MO). This pilot trial explores the capacity of a cooling cap (Elasto-gel) to prevent persistent alopecia in breast cancer patients treated with adjuvant docetaxel regimens.
Interventions
DEVICEelasto-gel cap
scalp cooling cap
Sponsors
Hospital San Carlos, Madrid
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* age 18-75 * breast cancer stages II-III * adjuvant or neoadjuvant chemotherapy with docetaxel regimens (TAC or anthracyclines followed by docetaxel 100 mg/m2 x 4)
Exclusion criteria
* contraindications for adjuvant docetaxel and or anthracyclines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage of patients without persistent alopecia | 2nd year following docetaxel chemotherapy |
Countries
Spain
Outcome results
None listed